-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
2 views
New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin\u2122 $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and addiction Option for an additional $20 million investment in Cynaptec Pharmaceuticals to support Phase 3 clinical development VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / June 17, 2025 / Lobe Sciences Ltd., (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a leading biopharmaceutical company focused on breakthrough treatments for rare diseases, is advancing the development of its novel compound, Conjugated Psilocin\u2122, following the April 14, 2025 spinout of the compound to the newly created Delaware corporation Cynaptec Pharmaceuticals, Inc. and signing of a key US$6 million investment non-brokered private placement agreement for preferred shares in Cynaptec Pharmaceuticals.
